Treatment of C4D-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin

Amish Shah, Tibor Nadasdy, Lois J Arend, James Brennan, Nufatt Leong, Myra Coppage, Mark Orloff, Richard Demme, Martin S. Zand

Research output: Contribution to journalArticle

Abstract

Background. Alloantibody-mediated acute rejection is a major cause of renal allograft loss despite aggressive therapy. Patients with humoral rejection can be identified with high sensitivity and specificity by the presence of peritubular capillary C4d staining on renal biopsy and donor-specific anti-human leukocyte antigen antibodies. Standard therapy for acute humoral rejection (AHR) has been removal of donor-specific antibodies by plasmapheresis (PPH) in conjunction with intravenous immunoglobulin therapy. We describe a series of seven patients with C4d positive AHR who received combined therapy with PPH and polyclonal rabbit antithymocyte globulin (rATG). Methods. PPH (1.4 volume exchange) was initiated on diagnosis of AHR on an alternate day basis for a mean number of 6.8 treatments, in conjunction with rATG (0.75 mg/kg/day 5-10 days) until the serum creatinine returned to 120% of nadir. Results. The nadir posttreatment creatinine was significantly lower than pretreatment creatinine (1.0±1.2 vs. 2±1.4, P

Original languageEnglish (US)
Pages (from-to)1399-1405
Number of pages7
JournalTransplantation
Volume77
Issue number9 SUPPL.
DOIs
StatePublished - May 15 2004

Fingerprint

Antilymphocyte Serum
Plasmapheresis
Rabbits
Creatinine
Tissue Donors
Kidney
Isoantibodies
Passive Immunization
Antibodies
Intravenous Immunoglobulins
Therapeutics
HLA Antigens
Allografts
Staining and Labeling
Biopsy
Sensitivity and Specificity
Serum

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Treatment of C4D-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. / Shah, Amish; Nadasdy, Tibor; Arend, Lois J; Brennan, James; Leong, Nufatt; Coppage, Myra; Orloff, Mark; Demme, Richard; Zand, Martin S.

In: Transplantation, Vol. 77, No. 9 SUPPL., 15.05.2004, p. 1399-1405.

Research output: Contribution to journalArticle

Shah, A, Nadasdy, T, Arend, LJ, Brennan, J, Leong, N, Coppage, M, Orloff, M, Demme, R & Zand, MS 2004, 'Treatment of C4D-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin', Transplantation, vol. 77, no. 9 SUPPL., pp. 1399-1405. https://doi.org/10.1097/01.TP.0000122187.76518.BC
Shah, Amish ; Nadasdy, Tibor ; Arend, Lois J ; Brennan, James ; Leong, Nufatt ; Coppage, Myra ; Orloff, Mark ; Demme, Richard ; Zand, Martin S. / Treatment of C4D-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. In: Transplantation. 2004 ; Vol. 77, No. 9 SUPPL. pp. 1399-1405.
@article{dd1c70028202492d8f789892c797d9e9,
title = "Treatment of C4D-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin",
abstract = "Background. Alloantibody-mediated acute rejection is a major cause of renal allograft loss despite aggressive therapy. Patients with humoral rejection can be identified with high sensitivity and specificity by the presence of peritubular capillary C4d staining on renal biopsy and donor-specific anti-human leukocyte antigen antibodies. Standard therapy for acute humoral rejection (AHR) has been removal of donor-specific antibodies by plasmapheresis (PPH) in conjunction with intravenous immunoglobulin therapy. We describe a series of seven patients with C4d positive AHR who received combined therapy with PPH and polyclonal rabbit antithymocyte globulin (rATG). Methods. PPH (1.4 volume exchange) was initiated on diagnosis of AHR on an alternate day basis for a mean number of 6.8 treatments, in conjunction with rATG (0.75 mg/kg/day 5-10 days) until the serum creatinine returned to 120{\%} of nadir. Results. The nadir posttreatment creatinine was significantly lower than pretreatment creatinine (1.0±1.2 vs. 2±1.4, P",
author = "Amish Shah and Tibor Nadasdy and Arend, {Lois J} and James Brennan and Nufatt Leong and Myra Coppage and Mark Orloff and Richard Demme and Zand, {Martin S.}",
year = "2004",
month = "5",
day = "15",
doi = "10.1097/01.TP.0000122187.76518.BC",
language = "English (US)",
volume = "77",
pages = "1399--1405",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9 SUPPL.",

}

TY - JOUR

T1 - Treatment of C4D-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin

AU - Shah, Amish

AU - Nadasdy, Tibor

AU - Arend, Lois J

AU - Brennan, James

AU - Leong, Nufatt

AU - Coppage, Myra

AU - Orloff, Mark

AU - Demme, Richard

AU - Zand, Martin S.

PY - 2004/5/15

Y1 - 2004/5/15

N2 - Background. Alloantibody-mediated acute rejection is a major cause of renal allograft loss despite aggressive therapy. Patients with humoral rejection can be identified with high sensitivity and specificity by the presence of peritubular capillary C4d staining on renal biopsy and donor-specific anti-human leukocyte antigen antibodies. Standard therapy for acute humoral rejection (AHR) has been removal of donor-specific antibodies by plasmapheresis (PPH) in conjunction with intravenous immunoglobulin therapy. We describe a series of seven patients with C4d positive AHR who received combined therapy with PPH and polyclonal rabbit antithymocyte globulin (rATG). Methods. PPH (1.4 volume exchange) was initiated on diagnosis of AHR on an alternate day basis for a mean number of 6.8 treatments, in conjunction with rATG (0.75 mg/kg/day 5-10 days) until the serum creatinine returned to 120% of nadir. Results. The nadir posttreatment creatinine was significantly lower than pretreatment creatinine (1.0±1.2 vs. 2±1.4, P

AB - Background. Alloantibody-mediated acute rejection is a major cause of renal allograft loss despite aggressive therapy. Patients with humoral rejection can be identified with high sensitivity and specificity by the presence of peritubular capillary C4d staining on renal biopsy and donor-specific anti-human leukocyte antigen antibodies. Standard therapy for acute humoral rejection (AHR) has been removal of donor-specific antibodies by plasmapheresis (PPH) in conjunction with intravenous immunoglobulin therapy. We describe a series of seven patients with C4d positive AHR who received combined therapy with PPH and polyclonal rabbit antithymocyte globulin (rATG). Methods. PPH (1.4 volume exchange) was initiated on diagnosis of AHR on an alternate day basis for a mean number of 6.8 treatments, in conjunction with rATG (0.75 mg/kg/day 5-10 days) until the serum creatinine returned to 120% of nadir. Results. The nadir posttreatment creatinine was significantly lower than pretreatment creatinine (1.0±1.2 vs. 2±1.4, P

UR - http://www.scopus.com/inward/record.url?scp=2442668988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442668988&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000122187.76518.BC

DO - 10.1097/01.TP.0000122187.76518.BC

M3 - Article

C2 - 15167598

AN - SCOPUS:2442668988

VL - 77

SP - 1399

EP - 1405

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9 SUPPL.

ER -